Stem Cell Therapies by D. Amat et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
  
8 
Stem Cell Therapies 
D. Amat1, J. Becerra2,3, M.A. Medina4,  
A.R. Quesada4 and M. Marí-Beffa2,3 
1Department of Human Anatomy,  
Faculty of Medicine, University of Malaga, Malaga, 
2Department of Cell Biology, Genetics and Physiology,  
Faculty of Science, University of Malaga, Malaga, 
3Networking Research Center on Bioengineering,  
Biomaterials and Nanomedicine, (CIBER-BBN), Malaga, 
4Department of Molecular Biology and Biochemistry,  
Faculty of Science, University of Málaga, Malaga,  
Spain 
1. Introduction 
Both development and adult homeostatic maintenance of different tissues and organs are 
dependent on the activity of a specific cell type named stem cell (SC). In recent years, SCs 
has been tested for clinical therapies against complex diseases. For many of these diseases, 
SC treatments offer a glimmer of hope. Fortunately, in some other instances, these therapies 
are an interesting reality. 
In this chapter, we aim to introduce the readers to the nature and diversity of SC. We will 
describe their origin and location in the human body and the main SC therapies used in 
clinical practice. Finally, we will propose a standard goal of current applications to convince 
readers about future avenues in these treatments. 
2. Stem cells 
2.1 Concept and types 
A stem cell is an undifferentiated cell that is able to proliferate, giving rise to various types 
of differentiating cell lineages. Through unequal divisions, SCs may predominantly give rise 
to two different cells: one SC and one progenitor cell which continues cell division to finally 
initiate cell differentiation. These are the two inherent features of the lineages of these cells, 
self-renewal and differentiation. Depending on their location and un-differentiation state, 
these cells are able to generate/restitute specific tissues, organs or complete embryos  
(Figure 1). This capacity is named potency. A stem cell shows a high potency when many 
different cell lines can be obtained in vitro or in vivo. SCs show reduced potency when very 
few cell lines can be obtained. 
According to this potency concept, SC can be classified into the following groups: 
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Totipotent stem cells: Cells able to differentiate into any embryonic or extra-embryonic cell 
line. Blastomeres from zygote to morula are totipotent cells. 
Pluripotent stem cells: Cells able to differentiate into any cell line derived from any of the 
three embryonic sheets. Cells of the Inner Cell Mass, the embryoblast, and cells of the 
germinal ridges are pluripotent SCs. 
Multipotent stem cells: Cells able to differentiate into any cell type derived from only one 
embryonic sheet. Ectoderm, endoderm or mesoderm stem cells are multipotent. 
 
Fig. 1. Cell potency varies during human embryogenesis and organogenesis.  
The zygote (1) and blastomeres at two cell stage (2) and morula (3) are totipotent cells. Cells 
in the inner mass of the blastocyst (4) are pluripotent. Trilaminar disc (5) cells are 
multipotent. Stem cells at heart or large bones (6) are either multipotent or unipotent. Green 
and yellow cells in the blastocyst respectively are trophoblast and inner cell mass. 
Under this classification, the embryo appears as a very important source of many different 
types of stem cells. Cells of the Inner Cell Mass are named Embryonic stem cells (ESCs, 
Thomson et al., 1998) and show a high potency. Besides, Adult (or Somatic) Stem Cells 
(ASCs) are resident cells in adult tissues all along the complete life span. These cells show a 
smaller potency than ESCs but lesser risks and bioethical problems (see below) during their 
clinical use. 
ASCs are responsible of adult tissue homeostasis. This homeostasis is established as a 
balance between cell death and cell proliferation. A clear example can be found in the skin. 
Superficial cell layers in the epidermis are continuously dying and being lost. In order to 
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maintain epidermis stability, basal cell layer continuously proliferate. This proliferation is 
carried out by a population of epidermal stem cells. 
In order to maintain tissue homeostasis, ASC show specific cell cycle properties. These cells 
are in a quiescent state. Under a wound stimulus, they proliferate and give rise to 
differentiated cell lineages. Cell proliferation and differentiation are compensated in such a 
way that new differentiated cells are proportionate to the original induction by wound 
signals.  Following a tissue injury and under new inducing signals released from the wound, 
ASC leave the quiescent state, proliferate and differentiate to replace damaged or dead cells. 
This natural process can restore absent or wounded tissues in few days. 
Modern Cell Biology technologies have also been able to induce potency in adult 
differentiated cells. By specific in vitro culturing conditions, differentiated cells can 
dedifferentiate and proliferate to initiate several newly-differentiating cell lines. These cells 
are named induced pluripotent stem cells (iPS, Takahashi et al., 2007). All above-
mentioned stem cells can be used in a potential cell therapy. 
2.2 Locations and functions 
Since the earliest stages of embryogenesis, stem cells can be inferred to occur. Blastomeres in 
all pre-morula stages are able to generate a complete organism when isolated from the rest. 
Thus, these blastomeres are the source of totipotent embryonic stem cells. A well-known 
example of this is both groups of blastomeres isolated to form two monozygotic twins 
during early development. Both resulting individuals are genetically identical and generate 
independent chorion, placenta and amniotic cavities. Thus, these monozygotic twins are 
also diamniotic, dichorionic and diplacental.  
Just before implantation, blastocysts form pluripotent stem cells in the Inner Cell mass or 
embryoblast. At this stage, a first cell commitment can be observed during human 
embryogenesis, the embryoblast is able to generate a complete organism but not the 
extraembryonic tissues. During embryoblast formation, the isolation of two inner cell 
masses also generates two monozygotic and diamniotic twins, but they are monochorionic 
and monoplacental. These unique structures are generated from a different embryonic tissue 
named trophoblast. 
Following this stage, the inner cell mass further specifies and moves their cells to form the 
embryonic sheets in two consecutive structures, the bilaminar and the trilaminar discs (see 
Figure 1). These three embryonic sheets, the ectoderm, the endoderm and the mesoderm, are 
formed by multipotent stem cells, committed to generate specific cell fates. Stem cells from 
any of these sheets are unable to differentiate into the typical fates of cells from other sheets 
(Thomson et al., 1998). 
The ectoderm forms the nervous system and the integument. In the adult, a group of 
ectoderm-derived stem cells can be found in the basal layer of the epidermis, the epidermal 
stem cells, and in sub-ventricular positions within the central nervous system, the neural 
stem cells. The former regulate a continuous epidermal renewal, whereas the latter maintain 
the cellular structure of the nervous tissue against a classical paradigm of nervous 
proliferative quiescence. Also associated to ectoderm, a derived embryonic source of stem 
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cells is found in the neural crest. During neural crest fusion, a group of ectodermal cells 
trans-differentiate into migratory derived cells and generate different cell types all along the 
body. These cell fates are skin melanocytes, facial bones and sensory neurons among others. 
This large migratory pathway can provide ectoderm-derived stem cells in peculiar locations 
such as carotid body, from which stem cells can be obtained to use them in therapies for 
Parkinson's disease.  
On the other hand, the endoderm gives rise to the respiratory and digestive systems. 
Endoderm-derived stem cells are multipotent and can be found in mucosae basal layer in 
both systems. These cells show a high cell proliferation rate and are continuously in risk to 
be affected by carcinogenic reagents. These reasons may have led these systems to show the 
highest neoplasia frequency of all human organs. In the human liver, another endoderm-
derived stem cell type can be found, the oval cells. These cells have been recently shown to 
be involved in hepatic-regeneration. A number of cell types can be differentiated from these 
oval cells, such as the hepatocytes or biliary duct cells.  
Finally, mesoderm is involved in the formation of many different apparatus or systems: the 
skeletal apparatus (bones, cartilage, tendons), the vascular system (blood, blood vessels and 
heart), excretory (nephric systems and kidney) and reproductive (gonads) systems and the 
whole connective tissue in the organism. Thus, many mesoderm-derived stem cells are also 
located in many locations in the body to form all these tissues. From a clinical point of view, 
optimal stem cells are those forming the blood, the haematopietic stem cells in the bone 
marrow, and mesenchymal stem cells which differentiate into muscle (myoblast), bone 
(osteoblast), cartilage (chondroblast), fat tissue (adipoblast) or fibroblast progenitor cells. 
These cell types can be found in any mesoderm-derived tissue. A special type of 
mesenchymal stem cells is umbilical cord stem cells that can be differentiated into blood or 
mesenchymal cells.  These stem cells from umbilical cord are a handy and bloodless source 
of highly proliferative stem cells useful for clinical purposes. 
2.2.1 Stem cell genetic program 
The knowledge of a genetic program for stem cells was initiated by two German 
embryologists, Theodor Boveri and Hans Driesch. In the late XIXs, both scientists 
respectively showed that the program was both located inside the nucleus and dependent 
on cell-to-cell interactions. Hans Driesch also proposed that the early embryo is a harmonic 
system in which all, or many, cells show the same potency which is dependent on cell-to-cell 
interactions. Modern Molecular and Developmental Biology are providing important 
information on the nuclear location of the genetic program and the cell-to-cell interaction-
dependence of animal embryogenesis.  
Any animal or human cell is also under the control of a genetic program. This genetic 
program is regulated by a hierarchy of transcription factors that either enhance or silence 
the activity of a single enzyme named the RNA polymerase II (Figure 2). This enzyme 
generates a heterogeneous RNA using as a substrate a DNA template in the open reading 
frame of the gene. This heterogeneous RNA is processed by RNA splicing and editing to 
generate the messenger RNA. In the ribosome, this messenger RNA is translated into 
protein. Protein synthesis requires a complete set of other specific proteins and RNAs to 
either form the ribosome or regulate its activity.  
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Fig. 2. A gene transcriptional hierarchy controls cell specification.  
At each stage, blue proteins to the right are RNA polymerase II enzymes. Protein complex in 
various colors is the general transcription complex. At each stage, isolated color boxes to the 
left (1 to 3) are specific transcription factors. Longer blue narrow rectangles are DNA strands 
and shorter yellow and dark blue narrow rectangles are messenger RNAs codifying for 
transcription factors in the same color. Explanations can be found in the text. 
The activity of the RNA polymerase II depends upon two different regulatory protein-
complexes, the general and the specific transcription complexes. The latter complexes are 
formed by the transcription factors (Figure 2) and co-factors. These proteins are able to bind 
DNA and step-by-step activate new downstream genes. Some of these new genes may 
codify for other transcription factors that activate further new downstream genes. Some of 
these transcription factors which act during animal embryogenesis are codified by genes 
named Hox, achaete, scute, engrailed, myoD, Dorsal, cubitus interruptus, apterous, Pannier or 
Iroquois. These animal proteins are ordered in a transcriptional hierarchy, the so-called 
genetic program (Figure 2). This hierarchy is so complex that almost all embryonic cells can 
be supposed to be different at the transcription level (See Alberts et al., 2007). Finally, this 
genetic program also transcribes mRNAs codifying for other protein types. These new 
proteins may be structural or collaborate in the regulation of many cell properties, such as 
cell division, apoptosis or differentiation. This completes the genetic control of 
embryogenesis or tissue maintenance.  
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Two additional features can be observed in animal development, cell-to-cell interaction 
dependence and pleiotropism. In animals, transcription regulation is balanced among all cells. 
This balanced regulation is able to generate cell diversity, organ size or pattern formation 
during embryogenesis. By this process, the transcription regulation of a given cell depends 
upon the transcription in surrounding cells. In order to balance these transcription activities, a 
number of different signal transduction pathways have been found (see Figure 3). Wnt, Sonic 
hedgehog, FGFs and BMPs are ligands that activate some of these transduction pathways.  
This balanced transcription can be traced back to the genome from the mother to regulate 
follicle cells signaling. Moreover, these proteins can interact with many other proteins in other 
cells to regulate many cell processes. Thus, the same ligands may pleiotropically regulate cell 
differentiation in ectoderm, endoderm and mesoderm-derived stem cells. The embryonic-
sheet specificity is provided by the genetic program of each cell. 
 
Fig. 3. Cell-to-cell interactions regulate gene transcription within each human cell.  
Signals can travel along varying distances. The upper left cell is a stem cell. The lower left 
and right cells respectively are a differentiating cell and a new stem cell. Details are 
described in text. 
These studies in animal species provide a good tool to now find human genes candidate to 
be regulating any cell process. By sequence similarity between any animal and human gene, 
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an orthologous human gene can be found. When compared with the animal gene, this 
human gene may also show similar functions in the human organism. 
When studying human stem cells, all these regulatory features can also be found. Notch or 
Wnt signaling pathways have  been shown to control the cell-to-cell-interaction-dependent 
decision between cell proliferation and cell differentiation.In humans, additional functions 
have been shown for these signaling pathways. The same can be found when other 
signaling pathways are studied. Transcription factors acting in stem cells are Bmi1, Oct4, 
SOX2, Klf-4, cMyc, FoxD3, or EGR1. An interesting effort might completely relate SC gene 
transcription to embryonic genetic program. 
In summary, the differentiation of any stem cell type depends on a hierarchy of 
transcription, traced back to maternal information. This hierarchical regulation also 
influences, in a balanced way, the differentiation of other surrounding cell types. These 
neighboring influences, such as the so-called stem cell niche, are under profound analysis.  
2.2.2 Stem cell niches 
Stem cells require a very specific chemical and physical environment for a correct function. 
This environment is provided by the Niche, a group of cells providing signals to stem cells 
for a balanced activity within the tissue (see Becerra et al., 2011).  
SC niche is defined as the microenvironment formed by SC, non-SC niche resident cells and 
specific signaling and ECM molecules surrounding them. The niche controls SC divisions. 
This SC proliferation can be regulated to fulfill the homeostatic needs (Becerra et al., 2011). 
Although the information on niche structure is still scarce, a recent increase in scientific 
publication on this topic is being issued. Drosophila testis or germarium, hair follicle, 
intestine crypts, bone marrow and brain sub-ventricular zone are niches under intense 
study (Fig. 4). 
Thus, the molecular/cellular paradigm is providing a new solution to one of the oldest 
unsolved questions in current developmental biology. Potency is now being understood 
under the concepts of genetic program and cell-to-cell interactions, and this may also help 
clinical practices. 
3. Cell therapies 
3.1 Introduction and concept 
An ancestral question, traced back much before ancient Greece, is to understand why 
human body does not regenerate. A Greek example is Prometheus legend. Prometheus was 
immortal but stole fire from Zeus and was condemned to be devoured by an eagle. The 
eagle ate his liver every day, but Prometheus continuously regenerated his organ back and 
back again. The ancient observation of living beings led to the idea of animal regeneration. 
Indeed, sea urchin, triton or fishes are able to regenerate their limbs to restitute previous 
amputations. This probably inspired the legend. 
The discovery and study of human stem cells brought about new hopes of recovering absent 
or injured organs. This was the birth of Cell therapy. Cell therapy is the treatment of 
www.intechopen.com
 
Embryology – Updates and Highlights on Classic Topics 
 
180 
human diseases by application of cells. Although this discipline is at its beginnings, many 
current therapies aim to use stem cells to treat an important variety of human diseases. 
 
Fig. 4. Simplified schematic representation of the niche of stem cells in the bone marrow.  
MSC and HSC interact in the endosteal niche, around the bone, and the vascular niche, close 
to the blood vessels. A lot of factors have been identified related to the regulation of 
hematopoiesis and the fate of the MSC. (1) spicules of bone, (2) osteoblasts, (3) 
hematopoietic stem cells (HSC), (4)Hematopoietic progenitor cells, (5) mesenchymal stem 
cells (MSC), (6) fenestrated capillaries, (7) progenitors inside capillaries, and (8) is an 
osteoclast.  
The above-mentioned cells, neural, respiratory or digestive mucosae stem cells, 
haematopoietic, epidermal, mesenchymal or umbilical cord stem cells are currently used to 
treat diseases. However, the methods for obtaining these cells and treatment effectiveness 
vary depending upon cell type or potency. 
In 1998, embryonic stem cells were first discovered (Thomson et al., 1998). Inner cell mass 
cells from a blastocyst were cultured in vitro. An empirical device was used to succeed in 
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this task. This empirical device was being used since 1960s for in vitro culture of animal 
cells. Fibroblasts were killed by irradiation inducing extensive mutations in their nuclei 
DNA. A lawn of irradiated fibroblasts was deposited in a Petri dish, the feeder layer, in 
order to feed the non-irradiated embryonic cells. During culturing, these cells spontaneously 
dissociated from one another. These living cells were sub-cultured in another feeder layer to 
obtain embryonic stem cell colonies. These cells showed an important pluripotency when 
induced to differentiate in vitro under a variety of different stimuli and eventually produced 
teratomas when grafted into a mouse. 
More modern techniques have been used to culture stem cells by in vitro amplification. 
Some of these cells can be obtained by egg enucleation and subsequent nuclear implantation 
from a differentiated somatic cell. If a pre-treatment of nutrient deprivation is carried out, 
nuclear re-programming may occur. This re-programming is able to de-differentiate the 
somatic cell nucleus and re-induce early embryogenesis in vitro. Under these conditions, a 
population of cultured cells from the patient can be obtained. Following these techniques, 
Asexually Produced Totipotent (APT) Cells were obtained. This technique shows a great 
advantage as these cells are not immunologically rejected when clinically used. 
Two experimental trials are used to verify the quality of embryonic stem cells: 
i. Teratome formation  
If ESCs are experimentally implanted in animals, they generate tumors. These tumors may 
differentiate structures such as gastric glands, teeth or hairs. The nature of these structures 
suggests that these tumors may be originated from any embryonic sheet. 
ii. Chimera induction  
If embryonic stem cells are implanted into a genetically different inner cell mass, a chimeric 
organism is formed. Although classical terminology states that chimeric organism are 
mixture of different species,ESC-derived chimerism only implies genetic differences within 
a given species. In these mammalian organisms, the cells show two different genomes. This 
may be useful to trace the location of cells by simple histological observations, but it can also 
be used as a cellular treatment of diseases. 
All these manipulations of human embryos or genes have precluded a direct application of 
these techniques due to bioethics reasons. Due to continuous argumentations in the society, 
an alternative to ESC use in cell therapies have arisen since the beginning. This technique 
use multipotent stem cells obtained from the adult, the above-mentioned ASC. Cell 
therapies using ASC has been widely expanded in clinical use around the world. However, 
although ASC are safe and very useful in many therapies, they show several practical 
problems that have to be considered. 
A first problem is related to methods to obtain ASCs. Almost any stem cell type has to be 
obtained by a different experimental protocol. Thus, there are simple ways and very difficult 
protocols of obtaining stem cells. The easiest protocol is bone marrow aspiration to obtain 
mesenchymal and haematopoietic stem cells. This is clinically used in everyday treatment of 
leukemia or blood cell diseases. The most difficult protocol is to obtain neural stem cells 
from sub-ependymal layers. The clinical protocols using this latter technique are far away 
from being regularly used at hospitals due to its low benefit/risk level. 
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Beside stem cells, these techniques normally require further auxiliary material. Among 
them, bioactive molecules and artificial scaffold are currently necessary for growth and cell 
differentiation to obtain tissue integration. All these auxiliary techniques are included in the 
so-called Tissue Engineering.  
3.2 Current applications 
Many different cell therapy techniques are currently under legalization process to be 
applied to treat modern diseases. Some of these diseases affect bone, cartilage, central 
nervous and immune systems, skin, heart or blood. Bone Marrow therapies to treat blood or 
skeletal diseases are widely spread treatments used all around the world. However, other 
cell therapies are still under intense research. These stem cell techniques are treating self-
immune or neurological diseases, such as Parkinson, ELA or medullar traumas. 
The most important factor boosting improvement of these treatments is the close-knit 
collaboration between basic and applied research. From basic research, model systems must 
be proposed to evaluate the effectiveness of cell therapy. These model systems require the 
definition of precise model species, organ, tissues and/or cell type to verify responses to 
treatments. Experimental conditions, such as transgenic mice, implanted animals or in vitro 
culturing, may also be necessary for this model system definition. In some instances, some 
of these techniques may also be applied to hospitals, where material useful for the definite 
cell treatment is necessary. During this process, biological research grants are substituted 
with pre-clinical trials, always under medical rigorousness and refereeing. Since most 
applications require ex vivo manipulation of cells collected from the donor, the European 
Union has regulated its use as a drug. 
In order to provide examples of this tortuous journey, we will discuss three examples. These 
three cell treatment examples use the same stem cell type, the mesoderm-derived 
mesenchymal stem cells (MSC). We will show that these three cases are elements in a single 
routing process that can be used as stepping stones to be followed when similar strategies 
are expected to be applied (Figure 5). 
The first therapy is widely used around the world. Every hospital has enough experience 
and tradition in its application. Moreover, citizens in modern societies have a clear 
knowledge of its existence and utility. This technique is Haematopietic stem cells 
implantation, or the well-known bone marrow transplantation. The second therapy is also 
well implanted in hospitals but it is rarer than previous ones. Although it has roots in 
ancient Egypt, there is not such a consensual application as HSC implantation. This is the 
use of mesenchymal stem cells in treatments of bone diseases. The third case is at pre-
clinical trials stage in some hospitals but it is widely unknown in clinical environments. This 
is the use of MSC to treat psoriasis or other angiogenic diseases. The three cases can be 
understood as a gradual process of accepting a unique clinical success. At this stage, the 
reconstruction of the original environment of stem cells in the body is reproduced and then 
these cells are able to restitute homeostasis in the organism. 
3.2.1 Cell therapy and haematopoiesis 
The tissue that generates blood cells is the Bone Marrow.  In the bone marrow, millions of 
HSC and MSC can be found. If after an accident, an important quantity of blood is lost,  
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Fig. 5. Bone marrow aspiration and liposuction provide mesenchymal stem cells.  
(A) bone marrow aspiration or liposuction, (B)  direct grafting of mesenchymal stem cells 
(mononuclear cell fraction), (C) in vitro amplification of progenitor cells, (D) grafting of 
amplified stem cells,  adsorbed on pieces of biomaterial (E)  and (F) potential treatment of a 
diabetic foot. 
signals are released at bone marrow to activate HSC. This activation induces cell 
proliferation and differentiation of the haematopoietic lineage to restore all blood cells. The 
restoring of blood cells is mandatory for reconstitution of blood in the injured patient. 
Following experiments with irradiated dogs, bone marrow transplantation was shown to be 
useful to restitute blood homeostasis. The physiological knowledge of the process has 
directed a clear improvement of treatments against hematological diseases. This treatment 
obtains bone marrow from healthy donors and implants them in compatible patients. Even 
though blood transfusions are commonly used due to mobilization of marrow progenitors 
to peripheral blood, bone marrow sources are iliac crests, sternum, femur and humerus. 
Bone marrow is the residence of millions of HSCs able to restitute these cells.  
Effectiveness of bone marrow transplantation can be easily studied in hematological 
diseases, such as congenital aplastic anemia, thalassemia, platelet defects or coagulopathy. 
In these instances, HSC at transplanted bone marrow restitute absent or defective blood cells 
in the patient (Figure 5). However, leukemia treatments provide additional information on 
this clinical strategy. This disease mostly affects white blood cells. In these diseases, white 
blood cells are present in the patient but they are in variable quantities suggesting loss of 
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regulation by uncontrolled proliferation. Bone marrow transplantation has also been 
important to treat leukemia. This cell therapy restores red blood cells and platelets 
previously reduced by chemical treatments. But this therapy also regulates abnormal HSC 
by substituting them with healthy HSC from donors. These healthy HSCs regulate patient 
haematopoiesis to homeostatic conditions. 
Millions of MSC, adipocytes or pericytes are still present in the irradiated host bone 
marrow. Some of these auxiliary cells may also help to generate a correct signaling ambient 
for the proliferation of cells to be up-regulated (Figure 4). Indeed, some of these cell types 
have been proposed to act as HSC Niche to provide a fine regulation of the restituting 
process. In the end, this fine regulation is crucial for homeostatic renewal and health 
restitution. This fine regulation of stem cells is the real standard goal of this technique. A 
tentative hypothesis would extend this standard goal to any other cell therapy method. 
Since this type of cell therapy does not perform ex vivo manipulation, they do not impose 
regulatory standards of drug quality. 
3.2.2 Cell therapy and chondrogenesis/osteogenesis 
In modern societies, a number of diseases have appeared associated to the new life style. The 
increase in life span brings about additional degenerative diseases, such as osteoporosis or 
arthritis, which affect bones and joints of an increasingly number of citizens. Moreover, traffic 
accidents or the massive play of sports also generates an important number of bone and joint 
diseases. These ostearticular patients are thus widely these ostearticular patients are widely 
distributed in the population and very different age groups can be affected by similar diseases. 
Although some evidence of limited digit regeneration has been reported in children, 
treatments for these diseases must be adapted to the special conditions of the patient.  
Cell therapy of partial bone or cartilage-defects, requires the in situ administration of 
osteoblast and chondroblast progenitor cells. These cells can also be obtained from bone 
marrow or other origins, amplified and induced in vitro into a osteo- or chondrogenic 
lineage. Then, these cells can easily be applied to the injured tissue (Figure 5). But, when 
surgeons transplanted these cells, they did not obtained proper results. Scaffolds to support 
cells and appropriate signals were not present and the skeletal tissue was not completely 
restored. A classical clinical practice was to obtain bone powder or small bone fragments 
and apply them to the operation field. Following this technique, a very important increase in 
bone regeneration was obtained. Then, surgeons transplanted a mixture of this powder and 
osteoblast progenitor cells to significantly improve bone regeneration. Even in these 
treatments, small or even larger pieces of bones were also transplanted in the mixture to 
gradually obtain better results. At this stage, a clear conclusion can also be obtained. Stem 
cells cannot fulfill a correct treatment by themselves, and a potential stem cell niche, either 
natural or artificial, to provide a necessary cell induction, must be present. 
Indeed, artificial biocompatible materials have also been extensively developed in this task. 
These biomaterials show superficial properties of special adherence to progenitor cells. 
Moreover, a number of different proteins, many in the TGF-beta super-family, can also be 
applied. These molecular treatments aim to reproduce the natural regulation of progenitor 
cells in the body and are combined with the cell therapy. This type of Tissue Engineering is 
one of the most promising techniques in this area. Pre-clinical and clinical trials are well 
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advanced and are showing significant results. As expected, these "artificial" treatments will 
be compared with "natural" ones after bone fragments transplantation, where cells, signals 
and extracellular matrix components are present. As the latter cannot always be applied due 
to the type of bone lesion, artificial scaffold treatments could be a candidate cell therapy in 
most hospitals in a short future. 
In general, these therapies take advantage of easy methods to obtain MSC. Bone Marrow 
aspiration is a well-founded medical technique. This technique can be applied to the 
patient and an important number of MSC obtained in vitro. These cells and the 
appropriate natural or artificial scaffold can hopefully collaborate in the regeneration of 
osteocartilage injuries. Recent alternatives to bone marrow aspiration can be found in 
liposuction techniques. Vasculo-stromal fraction from fat tissue obtained by this 
technique can be use as an in vitro source of MSCs. Potency and quality of these cells are 
enough to obtain osteoblasts or chondroblasts under the appropriate stimuli. But 
liposuction is less invasive than bone marrow aspiration and can further help the cosmetic 
surgery of the patient. In any case, cell therapy for skeletal repair is one of the most 
promising applications of regenerative medicine. 
3.2.3 Cell therapy and angiogenesis 
Angiogenesis is the generation of new capillaries by a process of sprouting of pre-existing 
microvessels. In health, vessel proliferation is under stringent control and occurs only 
during embryonic development, endometrial regulation, reproductive cycle and wound 
repair. On the contrary, a persistent and deregulated angiogenesis is related to diseases such 
as proliferative retinopathies, psoriasis and rheumatoid arthritis, and seems to be essential 
for tumor growth and metastasis (Carmeliet, 2005). On the other hand, the concept of 
therapeutic angiogenesis has emerged as an approach to ischemic diseases in which 
stimulation of new vessels growth is intended to restore blood supply to ischemic tissue 
(Carmeliet, 2005; Tirziu and Simons, 2005).  
Promising results in pre-clinical studies prompted the initiation of a number of clinical trials 
in patients with advanced coronary and peripheral arterial disease who had no other 
treatment option (Lachmann and Nikol, 2007; Tse et al., 2007). In spite of the recent 
advances in medical therapy, coronary artery disease remains the major cause of morbidity 
and mortality in the developing countries. In patients with severe coronary artery disease, 
persistent myocardial ischemia in hibernated myocardium can result in progressive loss of 
cardiomyocytes with development of heart failure. On the other hand, peripheral arterial 
disease is a common manifestation of systemic atherosclerosis that is associated with a 
significant limitation in limb function due to ischemia and high risk of cardiovascular 
mortality. The lower limb manifestations of peripheral arterial disease are classified into the 
categories of chronic stable claudication, critical leg ischemia, and acute limb ischemia. 
Lower limb ischemia is a major health problem since, in the absence of effective 
pharmacological, interventional or surgical treatment, amputation becomes the only 
solution to unbearable symptoms at the end-stage. 
A part of therapeutic angiogenesis approaches to treat coronary and peripheral artery 
diseases is based on cell therapy. Bone marrow consists of multiple cell populations, 
including endothelial progenitor cells, which have been shown to differentiate into 
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endothelial cells and release several angiogenic factors and thereby enhance 
neovascularisation in animal models of hind limb ischemia. The promising results from 
various preclinical studies provide the basis for clinical trials using bone marrow-derived 
cells or non-bone marrow cells, like cells from the peripheral blood or other tissues 
(Figure 5). However, the mechanisms by which these cells exert their positive effects are 
poorly understood (Lachmann and Nikol, 2007). Furthermore, although the initial pilot 
clinical trials showed potential clinical benefit of bone marrow derived cell therapy for 
therapeutic angiogenesis, the long-term safety, the optimal timing and treatment strategy 
remains unclear (Tse et al., 2007). This might explain why, up to the moment, some 
controversial results have been obtained. While a meta-analysis of randomized, controlled 
clinical trials of therapeutic angiogenesis published in 2009 concluded that patients with 
peripheral arterial disease -and in particular those with critical ischemia- improved their 
symptoms when treated with cell therapy with acceptable tolerability, a more recently 
published article concluded that stem cell or progenitor cell therapy did not reveal clinical 
benefit in patients with peripheral artery disease (De Haro et al., 2009; Nikol, 2011). 
Additional controlled clinical trials are in progress. When data from large randomized 
placebo-controlled trials will be available, it will be possible to evaluate properly the 
actual impact of this therapeutic approach. 
4. Risks and bioethics problems 
As any other medical treatment, cell therapy techniques may show intrinsic risks or lead to 
unexpected damages. First, to obtain adult MSC is bloody. Although it varies with the used 
technique, all methods show morbidity. Improvement can be found from Bone marrow 
aspiration to liposuction. The first technique is painful and shows potential surgical risks, 
whereas the second operation shows lesser morbidity although certain potential surgical 
complications can still arise. In any case, other alternatives show even worse side effects. 
Neural stem cells or liver oval cells can be obtained from an adult, but a complete 
neurosurgical or hepatic operation is necessary with many additional drawbacks. 
Obtaining the ASCs is not the whole problem. Stem cell implantation is another risky part of 
the protocol. When manipulating biological material during the surgical operation, the 
infection risk is very high. In order to reduce this risk, the surgeon and auxiliary 
manipulators has to follow strict conditions and actuations. All these risk does not preclude 
the application of these techniques. However, all implicated manipulators have to strictly 
follow many security protocols at each stage. Good Manufactured Practices (GMP) must be 
observed at all times. 
Moreover, postsurgical risks must also be considered. When heterologous grafts (donor and 
host are different persons) are carried out, immunological rejection is always important. 
Indeed, very severe diseases can appear such as Graft-against-Host disease or Systemic 
Inflammatory Response Syndrome which can drive to death to the patient. A continuous 
risk of cell treatments is to produce an uncontrolled growth in grafted cells to generate 
neoplasia. Statistically, the risk to suffer neoplasia is much lower when treated with ASC 
than using ESC. In ASC treatments, this probability is similar to that observed in untreated 
patients due to other carcinogenic factors. Recent findings indicate the MSCs produce 
recovery by trophic and immunomodulatory effects (Caplan, 2009). This has boosted 
numerous clinical trials that may hopefully lead to new healing therapies. 
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Another limiting question is posed by bioethics commissions. A big controversy arose with 
embryonic stem cells. To obtain these cells, embryos must be destroyed or their genetic 
material manipulated. This leads to moral problems which involves both the scientific 
community and the non-scientific society. Some countries approved these protocols whereas 
others did not. So, besides the moral questions, other economical-political reasons also 
influenced the natural development of these protocols. All this has led scientists and 
physicians to avoid the use of these cells in favor of ASCs.  
5. Future perspectives 
Besides all these improvements, Cell therapy has a long journey ahead. Among all obvious 
perspectives, to obtain Stem Cells through a lesser bloody operation, to find the appropriate 
stem cell source and to investigate the best signaling cocktail for any tissue differentiation, 
are clear options. In order to reach this, a continuous interaction between scientists and 
physicians must occur. If these therapies are approved for use in every hospital, GMP labs 
would be installed near the operating room. On the contrary, if marketing criteria are 
imposed, “therapeutic cells are drugs”, the situation will be very different.  
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